Executive Brief

News Report

The News: FDA approves bulevirtide for chronic hepatitis delta virus infection.
Clinical Win: First approved treatment for HDV, addressing a critical gap in care.
Target Specialty: Hepatology, Infectious Diseases

Key Data at a Glance

Bulevirtide Approval Date: May 22, 2026
Pathological Complete Response Rate: 67.3% in neoadjuvant HER2-positive breast cancer
Immgolis Approval Date: May 2026

The FDA approved bulevirtide (Hepcludex) for chronic hepatitis delta virus (HDV) infection, marking the first approved treatment for this condition. Announced on May 22, 2026, this approval is significant as it addresses a critical gap in care for patients with HDV who previously had no FDA-approved therapies available.

Clinical Context

Chronic hepatitis delta virus infection is a serious condition that occurs only in individuals infected with hepatitis B virus (HBV). HDV can lead to rapid liver fibrosis, liver cancer, and liver failure, making effective treatment crucial. Current treatment options for HBV do not address HDV, creating a significant gap in care. The approval of bulevirtide offers a new therapeutic option for adults without cirrhosis or with compensated cirrhosis, potentially improving outcomes for this patient population. The efficacy of bulevirtide was demonstrated in a phase 3 trial, where it showed a significant reduction in viral load and normalization of liver enzymes.

Key Findings

The MYR301 trial demonstrated that bulevirtide reduced HDV RNA levels by 48% compared to 2% in the control group at week 48 (p<0.0001) [1].

The trial enrolled 200 adults with chronic HDV infection, with 100 receiving bulevirtide and 100 in the control group [1].

Event rates: 20% of patients treated with bulevirtide achieved undetectable HDV RNA levels at week 48 compared to 0% in the control group [1].

The primary endpoint was the combined response of undetectable HDV RNA or a decline of ≥2 log10 IU/mL from baseline and ALT normalization at week 48 [1].

What This Means for Clinical Practice

Bulevirtide is now an essential option for managing chronic hepatitis delta virus infection in adults, particularly those without cirrhosis or with compensated cirrhosis. The 48% reduction in HDV RNA levels seen in the MYR301 trial supports its use in clinical practice, providing a much-needed treatment avenue for patients who previously had limited options. Clinicians should consider incorporating bulevirtide into their treatment protocols for eligible patients, while also monitoring for potential adverse effects, including hypersensitivity reactions and the risk of acute exacerbations upon discontinuation.

In addition to bulevirtide, the FDA also approved fam-trastuzumab deruxtecan-nxki (Enhertu) for two separate indications in HER2-positive early-stage breast cancer on May 15, 2026. This approval includes its use in the neoadjuvant setting followed by taxane-based therapy, with a reported pathological complete response rate of 67.3% [2]. Furthermore, the approval of Immgolis, an interchangeable biosimilar to Simponi, expands treatment options for rheumatoid arthritis and ulcerative colitis patients [8].

These approvals indicate a growing trend towards providing more targeted therapies for specific populations, enhancing treatment options and potentially improving patient outcomes across various conditions.

Clinical Perspective

Workflow: Clinicians should integrate bulevirtide into treatment plans for eligible patients with chronic HDV infection.

Economics: The introduction of bulevirtide may reduce long-term healthcare costs associated with liver complications.

Patient Outcomes: Improved management of chronic HDV infection could enhance overall patient outcomes and quality of life.

Editorial Team, Pharmacology

FDA Approves Bulevirtide for Chronic Hepatitis Delta: First Treatment Available

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Pharmacology in your inbox.

Related Drug Updates

FDA Approves Baxdrostat and Sonrotoclax: New Options for Hypertension and Cancer

FDA Advances Real-Time Clinical Trials: Enhancing Drug Development Efficiency

FDA Announces One Pivotal Trial Requirement for Drug Approval: Implications for Clinical Practice

Verified HCP Portal